Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
7502738 | Drug and Alcohol Dependence | 2018 | 37 Pages |
Abstract
Studies were heterogeneous with respect to sample selection, sample size, and outcome measures. Medications targeting insomnia yielded mixed results. Similarly, studies of agents targeting anxiety symptoms demonstrated inconsistent findings in the reduction of anxiety, improvement in withdrawal symptoms, or enhancement of benzodiazepine completion rates. Anticonvulsants have supporting evidence from small case reports; carbamazepine shows some potential in assisting taper completion and reducing withdrawal severity. These conclusions should be considered in light of a number of inconsistencies across studies in the literature. The results of this review article highlight the need for additional research on optimal strategies for facilitating successful benzodiazepine tapers.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Justine W. Welsh, Valeria Tretyak, R. Kathryn McHugh, Roger D. Weiss, Olivera Bogunovic,